vs
Apellis Pharmaceuticals, Inc.（APLS）与shutterstock没有广泛通用的标准中文译名，所以这里是null（SSTK）财务数据对比。点击上方公司名可切换其他公司
shutterstock没有广泛通用的标准中文译名，所以这里是null的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$220.2M vs $199.9M），shutterstock没有广泛通用的标准中文译名，所以这里是null净利率更高（-7.3% vs -29.5%，领先22.2%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -12.0%），shutterstock没有广泛通用的标准中文译名，所以这里是null自由现金流更多（$25.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Shutterstock是一家总部位于美国纽约的素材服务提供商，由程序员兼摄影师乔恩·奥林格于2002年创立。平台拥有约2亿张免版税的图片、矢量图与插画素材，另有超千万条视频剪辑和音乐曲目可供授权使用，同时也为用户提供编辑工具服务，业务模式已从最初仅支持订阅拓展出单点购买选项。
APLS vs SSTK — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $220.2M |
| 净利润 | $-59.0M | $-16.0M |
| 毛利率 | — | 55.8% |
| 营业利润率 | -25.6% | -1.1% |
| 净利率 | -29.5% | -7.3% |
| 营收同比 | -5.9% | -12.0% |
| 净利润同比 | -62.2% | -1021.0% |
| 每股收益（稀释后） | $-0.40 | $-0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $220.2M | ||
| Q3 25 | $458.6M | $260.1M | ||
| Q2 25 | $178.5M | $267.0M | ||
| Q1 25 | $166.8M | $242.6M | ||
| Q4 24 | $212.5M | $250.3M | ||
| Q3 24 | $196.8M | $250.6M | ||
| Q2 24 | $199.7M | $220.1M | ||
| Q1 24 | $172.3M | $214.3M |
| Q4 25 | $-59.0M | $-16.0M | ||
| Q3 25 | $215.7M | $13.4M | ||
| Q2 25 | $-42.2M | $29.4M | ||
| Q1 25 | $-92.2M | $18.7M | ||
| Q4 24 | $-36.4M | $-1.4M | ||
| Q3 24 | $-57.4M | $17.6M | ||
| Q2 24 | $-37.7M | $3.6M | ||
| Q1 24 | $-66.4M | $16.1M |
| Q4 25 | — | 55.8% | ||
| Q3 25 | — | 60.6% | ||
| Q2 25 | — | 60.3% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.1% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 58.8% |
| Q4 25 | -25.6% | -1.1% | ||
| Q3 25 | 48.7% | 12.5% | ||
| Q2 25 | -18.6% | 13.0% | ||
| Q1 25 | -50.0% | 4.2% | ||
| Q4 24 | -12.3% | 5.3% | ||
| Q3 24 | -24.0% | 7.2% | ||
| Q2 24 | -14.7% | 9.4% | ||
| Q1 24 | -36.0% | 7.8% |
| Q4 25 | -29.5% | -7.3% | ||
| Q3 25 | 47.0% | 5.1% | ||
| Q2 25 | -23.6% | 11.0% | ||
| Q1 25 | -55.3% | 7.7% | ||
| Q4 24 | -17.1% | -0.6% | ||
| Q3 24 | -29.2% | 7.0% | ||
| Q2 24 | -18.9% | 1.6% | ||
| Q1 24 | -38.5% | 7.5% |
| Q4 25 | $-0.40 | $-0.47 | ||
| Q3 25 | $1.67 | $0.37 | ||
| Q2 25 | $-0.33 | $0.82 | ||
| Q1 25 | $-0.74 | $0.53 | ||
| Q4 24 | $-0.30 | $-0.04 | ||
| Q3 24 | $-0.46 | $0.50 | ||
| Q2 24 | $-0.30 | $0.10 | ||
| Q1 24 | $-0.54 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $178.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $581.0M |
| 总资产 | $1.1B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $178.2M | ||
| Q3 25 | $479.2M | $165.5M | ||
| Q2 25 | $370.0M | $116.4M | ||
| Q1 25 | $358.4M | $112.2M | ||
| Q4 24 | $411.3M | $111.3M | ||
| Q3 24 | $396.9M | $131.4M | ||
| Q2 24 | $360.1M | $74.9M | ||
| Q1 24 | $325.9M | $71.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $581.0M | ||
| Q3 25 | $401.2M | $594.4M | ||
| Q2 25 | $156.3M | $586.2M | ||
| Q1 25 | $164.2M | $547.2M | ||
| Q4 24 | $228.5M | $518.4M | ||
| Q3 24 | $237.1M | $522.9M | ||
| Q2 24 | $264.3M | $520.4M | ||
| Q1 24 | $266.7M | $541.3M |
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $821.4M | $1.4B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.3B | ||
| Q3 24 | $901.9M | $1.3B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | $1.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $36.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $25.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 11.8% |
| 资本支出强度资本支出/营收 | 0.1% | 4.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $123.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $36.2M | ||
| Q3 25 | $108.5M | $78.4M | ||
| Q2 25 | $4.4M | $26.8M | ||
| Q1 25 | $-53.4M | $25.2M | ||
| Q4 24 | $19.4M | $8.0M | ||
| Q3 24 | $34.1M | $-11.6M | ||
| Q2 24 | $-8.3M | $28.0M | ||
| Q1 24 | $-133.0M | $8.3M |
| Q4 25 | $-14.3M | $25.9M | ||
| Q3 25 | $108.3M | $68.0M | ||
| Q2 25 | $4.4M | $15.5M | ||
| Q1 25 | $-53.4M | $14.4M | ||
| Q4 24 | $19.3M | $-952.0K | ||
| Q3 24 | — | $-26.3M | ||
| Q2 24 | $-8.4M | $18.9M | ||
| Q1 24 | $-133.3M | $-6.2M |
| Q4 25 | -7.1% | 11.8% | ||
| Q3 25 | 23.6% | 26.1% | ||
| Q2 25 | 2.5% | 5.8% | ||
| Q1 25 | -32.0% | 6.0% | ||
| Q4 24 | 9.1% | -0.4% | ||
| Q3 24 | — | -10.5% | ||
| Q2 24 | -4.2% | 8.6% | ||
| Q1 24 | -77.3% | -2.9% |
| Q4 25 | 0.1% | 4.7% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.0% | 4.5% | ||
| Q4 24 | 0.0% | 3.6% | ||
| Q3 24 | 0.0% | 5.9% | ||
| Q2 24 | 0.0% | 4.1% | ||
| Q1 24 | 0.2% | 6.7% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 5.86× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.66× | ||
| Q2 24 | — | 7.71× | ||
| Q1 24 | — | 0.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SSTK
暂无分部数据
